Affiliation:
1. Department of Cell Biology NYU School of Medicine New York NY USA
2. Department of Microbiology NYU School of Medicine New York NY USA
Abstract
The diarylquinoline bedaquiline (BDQ) is an FDA‐approved drug for the treatment of multidrug‐resistant tuberculosis that targets the mycobacterial adenosine triphosphate (ATP) synthase, a key enzyme in cellular respiration. In a recent study, Courbon et al (2023) examine the interaction between Mycobacterium smegmatis ATP synthase with the second generation diarylquinoline TBAJ‐876 and the squaramide inhibitor SQ31f, showing that both drugs prevent the rotatory motions needed for enzymatic function.
Publisher
Springer Science and Business Media LLC
Subject
General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,Molecular Biology,General Neuroscience